Stéphane Bancel, Moderna CEO (Lenin Nolly/NurPhoto via AP Images)
September 12, 2024 06:00 AM EDTUpdated 09:33 AM
R&D

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Andrew Dunn

Senior Biopharma Correspondent

Stéphane Ban­cel has re­lent­ed to Wall Street’s de­sire for cost-cut­ting and rein­ing in Mod­er­na’s pipeline.

To kick off its an­nu­al R&D day in New York …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times